Replies to post #252725 on Biotech Values

[DewDiligence]

MYNZ +27% on TMO development/commercialization deal—no financial terms disclosed:

https://www.globenewswire.com/news-release/2024/11/12/2979299/0/en/Mainz-Biomed-and-Thermo-Fisher-Scientific-Sign-a-Collaboration-Agreement-for-the-Development-of-Next-Generation-Colorectal-Cancer-Screening-Product-for-Global-Markets.html

The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed’s Next Generation colorectal cancer screening product. The collaboration will harness Thermo Fisher’s powerful technologies, instrumentation and information translation systems to enable Mainz Biomed to develop the proprietary assays for its mRNA-based next-generation CRC screening tests…